Fresenius Medical Care AG & Co. KGaA FMS

22.69 0.34 1.52% as of 25 Sep
Market cap
$11.9B
P/E
11.8×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
22,206.67 20,923.39 21,054.65 20,437.75 20,844.67 20,400.41 19,573.74 19,541.86 20,100.77 17,910.79
Revenue Growth
6.13% (0.62%) 3.02% (1.95%) 2.18% 4.22% 0.16% (2.78%) 12.23% 7.01%
Cost of Revenue
16,516.94 15,776.21 15,724.32 14,842.87 14,838.03 14,074.98 13,530.39 13,454.11 13,314.77 12,131.15
Gross Profit
5,689.73 5,147.17 5,330.33 5,594.88 6,006.63 6,325.42 6,043.35 6,087.75 6,786.01 5,779.64
R&D Expenses
178.73 198.56 251.06 240.88 261.21 221.35 188.19 157.80 147.73 162.36
SG&A Expenses
3,431.23 3,400.84 3,459.40 3,987.49 3,663.03 3,614.88 3,428.02 3,384.37 4,043.96 3,044.66
Operating Income
2,067.11 1,506.71 1,482.14 1,592.78 2,191.45 2,632.33 2,541.91 3,587.64 2,670.27 2,637.52
Non-operating Income/Expense
(356.16) (363.01) (364.11) (308.15) (331.78) (420.39) (480.98) (355.55) (400.00) (405.53)
Non-operating Interest Expenses
434.92 440.46 459.59 379.44 418.34 468.32 549.99 529.64 448.94 452.18
EBT
1,710.95 1,143.70 1,118.03 1,284.63 1,859.67 2,211.94 2,060.93 3,232.09 2,270.26 2,231.99
Income Tax Provision
363.15 342.00 325.29 342.37 417.44 571.79 449.81 603.58 513.17 683.14
Income after Tax
1,347.80 801.70 792.74 942.26 1,442.23 1,640.15 1,611.12 2,628.50 1,757.09 1,548.85
Dividends (Preferred)
0.00 — — 0.00 — — — — 0.00 —
Non-Controlling Interest
240.88 219.62 252.67 232.76 295.44 310.08 267.55 287.85 310.55 305.58
Net Income Common
1,106.92 582.08 540.06 709.50 1,146.79 1,330.07 1,343.57 2,340.65 1,446.54 1,243.27
EPS (Basic)
1.90 0.98 0.92 1.21 1.96 2.26 2.22 3.80 2.36 2.03
EPS (Diluted)
1.90 0.98 0.92 1.21 1.96 2.26 2.22 3.80 2.36 2.03
Shares (Basic, Weighted)
582.38 586.83 586.83 586.49 585.89 588.11 605.38 613.08 613.13 611.50
Shares (Diluted, Weighted)
582.38 586.83 586.83 586.49 586.13 588.56 605.50 614.45 614.57 612.52
Gross Margin
25.62% 24.60% 25.32% 27.38% 28.82% 31.01% 30.87% 31.15% 33.76% 32.27%
EBIT Margin
9.31% 7.20% 7.04% 7.79% 10.51% 12.90% 12.99% 18.36% 13.28% 14.73%
EBT margin
7.70% 5.47% 5.31% 6.29% 8.92% 10.84% 10.53% 16.54% 11.29% 12.46%
Net Profit Margin
4.98% 2.78% 2.57% 3.47% 5.50% 6.52% 6.86% 11.98% 7.20% 6.94%
Free Cash Flow Margin
9.08% 8.80% 10.08% 7.63% 9.42% 17.90% 8.32% 6.40% 7.59% 6.30%
EBITDA
3,764.67 3,392.01 3,378.30 3,529.68 4,112.42 4,672.36 4,326.25 4,443.69 3,501.58 3,413.47
EBIT
2,067.11 1,506.71 1,482.14 1,592.78 2,191.45 2,632.33 2,541.91 3,587.64 2,670.27 2,637.52
Income from Continuous Operations
1,347.80 801.70 792.74 942.26 1,442.23 1,640.15 1,611.12 2,628.50 1,757.09 1,548.85
Consolidated Net Income/Loss
1,347.80 801.70 792.74 942.26 1,442.23 1,640.15 1,611.12 2,628.50 1,757.09 1,548.85
EPS (Basic, from Continuous Ops)
2.31 1.37 1.35 1.61 2.46 2.79 2.66 4.29 2.87 2.53
EPS (Basic, Consolidated)
2.31 1.37 1.35 1.61 2.46 2.79 2.66 4.29 2.87 2.53
EPS (Diluted, from Cont. Ops)
2.31 1.37 1.35 1.61 2.46 2.79 2.66 4.28 2.86 2.53
Shares (Diluted, Average)
582.38 587.98 586.83 586.49 585.89 588.11 605.38 612.67 612.44 611.50
EPS (Diluted, Consolidated)
2.31 1.37 1.35 1.61 2.46 2.79 2.66 4.28 2.86 2.53
EBITDA Margin
16.95% 16.21% 16.05% 17.27% 19.73% 22.90% 22.10% 22.74% 17.42% 19.06%
Operating Cash Flow Margin
13.66% 12.34% 13.51% 11.17% 14.13% 23.70% 14.69% 12.46% 12.32% 11.95%

Fold the line items

In millions of $ except per-share values · columns are period end dates